Elizabeth Nabel is an American cardiologist and Executive Vice President of Strategy at ModeX Therapeutics and OPKO Health.

She graduated summa cum laude from St. Olaf in 1974 and earned her MD degree from Weill Cornell Medical College in 1981.

As director of the NIH’s National Heart, Lung, and Blood Institute from 2005 to 2009, Nabel had a history of advocacy and broadening access to care.

In 2010, Nabel returned to Brigham and Women’s Hospital as president and Professor of Medicine at Harvard Medical School.

[11] Nabel's studies on Hutchinson-Gilford progeria syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke.

[12] In November 2020, the U.S. Food and Drug Administration approved lonafarnib, which helps prevent buildup of defective progerin and similar proteins.

Nabel serves on the Boards of Medtronic,[17] Moderna,[18] Lyell,[19] Accolade,[20] the Lasker Foundation,[21] and South Florida PBS.

She has helped guide the company through its formative stages and facilitated the development of its technologies, including Moderna’s generation of its COVID vaccine.

Supporting [Partners in Health], Nabel helped create and open Butaro Hospital in Northern Rwanda in 2011.